

Approved



Vietnam
Country Operational Plan
FY 2017



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		240,515		240,515	300,000	540,515
USAID		16,707,168		16,707,168	6,682,228	23,389,396
DOD		0		0	1,611,380	1,611,380
HHS/CDC	1,857,750	10,709,899		12,567,649	6,973,079	19,540,728
HHS/HRSA		0		0	58,000	58,000
HHS/SAMHSA		1,256,730		1,256,730	0	1,256,730
State/EAP		0		0	50,000	50,000
Total	1,857,750	28,914,312	0	30,772,062	15,674,687	46,446,749

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	State/EAP	DOD	HHS/CDC	HHS/HRSA	HHS/SAMHSA	USAID		
HBHC	9,052		0	540,971	0	44,383	177,475	0	771,881
HLAB			0	787,115			0	0	787,115
HMBL			0					0	0
HMIN			0					0	0
HTXD							7,598,765	0	7,598,765
HTXS	10,560		0	5,938,828	0		2,532,780	0	8,482,168
HVCT	7,543		0	1,972,208			1,192,547	0	3,172,298
HVMS	198,273		0	197,128		290,836	1,331,076	0	2,017,313
HVOP	3,017	0	0	506,952			1,331,364	0	1,841,333
HVSI	1,509		0	974,579			674,138	0	1,650,226

Approved



HVTB	3,017		0	664,538	0		112,798	0	780,353
IDUP	4,526			225,236		672,719	485,385	0	1,387,866
MTCT	1,509		0	155,179				0	156,688
OHSS	1,509		0	269,354		248,792	1,251,701	0	1,771,356
PDCS				110,136			6,380	0	116,516
PDTX				225,425			12,759	0	238,184
	240,515	0	0	12,567,649	0	1,256,730	16,707,168	0	30,772,062



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	381,190	0
HVTB	637,047	0
PDCS	116,516	0
Total Technical Area Planned Funding:	1,134,753	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	642,625	0
HVSI	1,282,442	0
OHSS	1,572,083	0
Total Technical Area Planned Funding:	3,497,150	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	0	0
HMIN	0	0
HVCT	2,882,149	0
HVOP	1,709,036	0
IDUP	1,017,401	0
MTCT	155,179	0
Total Technical Area Planned Funding:	5,763,765	0

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	7,554,318	0
HTXS	7,441,155	0
PDTX	238,184	0
Total Technical Area Planned Funding:	15,233,657	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2018
KP_MAT_TA	KP_MAT_TA Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	10,870
	Sex: Female	186
	Sex: Male	10,684
	Sum of Sex Disaggregates	10,870
	Unknown Sex	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,700
	Male 10-14	
	Male 15-19	
	Male 20-24	1,070
	Male 25-49	380
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	150



	Female 25-49	100
	Female 50+	
	(15-19)	
	(20-24)	
	FSW	
	MSM	
	TG	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	87,387
	Total number of people in the target population	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	51
	Age/sex: 20-24 Male	50,841
	Age/sex: 25-49 Male	3,115
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	1,448
	Age/sex: 20-24 Female	2,954
	Age/sex: 25-49 Female	28,978
	Age/sex: 50+ Female	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
Aggregated Age/sex: <15 Female		



	Aggregated Age/sex: 15+ Female	
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,028
	Total number of people in the target population	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	32
	Age/sex: 20-24 Male	224
	Age/sex: 25-49 Male	1,252
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	105
	Age/sex: 20-24 Female	530
	Age/sex: 25-49 Female	2,885
	Age/sex: 50+ Female	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a



	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	81,051
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,563
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	24,596
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	188
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with	1,061



	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,094
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	43,683
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,866
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	



	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID)	



	(Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	7,681



	required	
	Total estimated number of key population in the catchment area	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,441
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	240
	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	72
	By key population type: Men who	1,904



	<p>have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>4</p>
	<p>By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>20</p>
	<p>By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)</p>	
	<p>By key population type: Males who</p>	



	inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known positive	



	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	65,155
	By Test Result: Positive	1,838
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	



	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Male,	



	Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Homebased testing: <1, Negative	
	Service Delivery Point (Community) Homebased testing: <1, Positive	
	Service Delivery Point (Community) Homebased testing: 1-9, Negative	
	Service Delivery Point (Community) Homebased testing: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing:	



	<15, Male, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	



	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point (Facility)	



	Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: <1, Negative	
	Service Delivery Point (Facility) Inpatient: <1, Positive	
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Positive	
	Service Delivery Point Agg Age	



	(Facility) Inpatient: 15+, Male, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Malnutrition: Negative	
	Service Delivery Point (Facility) Malnutrition: Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female,	



	Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	
	Service Delivery Point (Community)	



	Mobile Testing: 50+, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: <1, Negative	
	Service Delivery Point (Community) Mobile Testing: <1, Positive	
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15,	



	Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	
	Service Delivery Point (Facility)	



	Other PITC: 10-14, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	



	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: <1, Negative	
	Service Delivery Point (Facility) Other PITC: <1, Positive	
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	
	Service Delivery Point Agg Age	



	(Facility) Other PITC: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	9,424
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	20
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	20,090
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	86
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: 10-14, Female, Negative	
	Service Delivery Point (Community)	



	Other: 10-14, Female, Positive	
	Service Delivery Point (Community)	
	Other: 10-14, Male, Negative	
	Service Delivery Point (Community)	
	Other: 10-14, Male, Positive	
	Service Delivery Point (Community)	
	Other: 15-19, Female, Negative	
	Service Delivery Point (Community)	
	Other: 15-19, Female, Positive	
	Service Delivery Point (Community)	
	Other: 15-19, Male, Negative	
	Service Delivery Point (Community)	
	Other: 15-19, Male, Positive	
	Service Delivery Point (Community)	
	Other: 20-24, Female, Negative	
	Service Delivery Point (Community)	
	Other: 20-24, Female, Positive	
	Service Delivery Point (Community)	
	Other: 20-24, Male, Negative	
	Service Delivery Point (Community)	
	Other: 20-24, Male, Positive	
	Service Delivery Point (Community)	
	Other: 25-49, Female, Negative	
	Service Delivery Point (Community)	
	Other: 25-49, Female, Positive	
	Service Delivery Point (Community)	
	Other: 25-49, Male, Negative	
	Service Delivery Point (Community)	
	Other: 25-49, Male, Positive	
	Service Delivery Point (Community)	
	Other: 50+, Female, Negative	
	Service Delivery Point (Community)	
	Other: 50+, Female, Positive	
	Service Delivery Point (Community)	



	Other: 50+, Male, Negative	
	Service Delivery Point (Community) Other: 50+, Male, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: <1, Negative	
	Service Delivery Point (Community) Other: <1, Positive	
	Service Delivery Point (Community) Other: 1-9, Negative	
	Service Delivery Point (Community) Other: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Other: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Other: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Other: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Other: <15, Male, Positive	



	Service Delivery Point Agg Age (Community) Other: 15+, Female, Negative	558
	Service Delivery Point Agg Age (Community) Other: 15+, Female, Positive	12
	Service Delivery Point Agg Age (Community) Other: 15+, Male, Negative	1,148
	Service Delivery Point Agg Age (Community) Other: 15+, Male, Positive	48
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Pediatric : <5 Negative	
	Service Delivery Point (Facility) Pediatric : <5 Positive	
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	
	Service Delivery Point (Facility) TB:	



	10-14, Male, Positive	
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	
	Service Delivery Point (Facility) TB: 25-49, Female, Negative	
	Service Delivery Point (Facility) TB: 25-49, Female, Positive	
	Service Delivery Point (Facility) TB: 25-49, Male, Negative	
	Service Delivery Point (Facility) TB: 25-49, Male, Positive	
	Service Delivery Point (Facility) TB: 50+, Female, Negative	
	Service Delivery Point (Facility) TB: 50+, Female, Positive	
	Service Delivery Point (Facility) TB: 50+, Male, Negative	
	Service Delivery Point (Facility) TB: 50+, Male, Positive	
	Service Delivery Point (Facility) TB:	



	Unknown Age, Female, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) TB: <1, Negative	
	Service Delivery Point (Facility) TB: <1, Positive	
	Service Delivery Point (Facility) TB: 1-9, Negative	
	Service Delivery Point (Facility) TB: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	63
	Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	159
	Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	490
	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	
	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	1,201
	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	
	Service Delivery Point Agg Age	



	(Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VMMC: <1, Negative	
	Service Delivery Point (Facility) VMMC: <1, Positive	
	Service Delivery Point (Facility) VMMC: 10-14, Negative	
	Service Delivery Point (Facility) VMMC: 10-14, Positive	
	Service Delivery Point (Facility) VMMC: 15-19, Negative	
	Service Delivery Point (Facility) VMMC: 15-19, Positive	
	Service Delivery Point (Facility) VMMC: 1-9, Negative	
	Service Delivery Point (Facility) VMMC:	
	Service Delivery Point (Facility) VMMC: 20-24, Negative	
	Service Delivery Point (Facility) VMMC: 20-24, Positive	
	Service Delivery Point (Facility) VMMC: 25-49, Negative	
	Service Delivery Point (Facility)	



	VMMC: 25-49, Positive	
	Service Delivery Point (Facility) VMMC: 50+, Negative	
	Service Delivery Point (Facility) VMMC: 50+, Positive	
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point Agg Age (Facility) VMMC: <15, Negative	
	Service Delivery Point Agg Age (Facility) VMMC: <15, Positive	
	Service Delivery Point Agg Age (Facility) VMMC: 15+, Negative	
	Service Delivery Point Agg Age (Facility) VMMC: 15+, Positive	
	Service Delivery Point Agg Age (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point Agg Age (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	
	Service Delivery Point (Facility)	



	Index: 15-19, Female, Positive	
	Service Delivery Point (Facility)	
	Index: 15-19, Male, Negative	
	Service Delivery Point (Facility)	
	Index: 15-19, Male, Positive	
	Service Delivery Point (Facility)	
	Index: 20-24, Female, Negative	
	Service Delivery Point (Facility)	
	Index: 20-24, Female, Positive	
	Service Delivery Point (Facility)	
	Index: 20-24, Male, Negative	
	Service Delivery Point (Facility)	
	Index: 20-24, Male, Positive	
	Service Delivery Point (Facility)	
	Index: 25-49, Female, Negative	
	Service Delivery Point (Facility)	
	Index: 25-49, Female, Positive	
	Service Delivery Point (Facility)	
	Index: 25-49, Male, Negative	
	Service Delivery Point (Facility)	
	Index: 25-49, Male, Positive	
	Service Delivery Point (Facility)	
	Index: 50+, Female, Negative	
	Service Delivery Point (Facility)	
	Index: 50+, Female, Positive	
	Service Delivery Point (Facility)	
	Index: 50+, Male, Negative	
	Service Delivery Point (Facility)	
	Index: 50+, Male, Positive	
	Service Delivery Point (Facility)	
	Index: Unknown Age, Female, Negative	
	Service Delivery Point (Facility)	
	Index: Unknown Age, Female,	



	Positive	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Index: <1, Negative	
	Service Delivery Point (Facility) Index: <1, Positive	
	Service Delivery Point (Facility) Index: 1-9, Negative	
	Service Delivery Point (Facility) Index: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	



	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	
	By Key Population: FSW, Negative	
	By Key Population: FSW, Positive	
	By Key Population: MSM, Negative	
	By Key Population: MSM, Positive	
	By Key Population: People in prisons and other enclosed settings, Negative	
	By Key Population: People in prisons and other enclosed settings, Positive	
	By Key Population: PWID, Negative	
	By Key Population: PWID, Positive	
	By Key Population: TG, Negative	
	By Key Population: TG, Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	



	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	
	Service Delivery Point (Community)	



	Index Mod: 50+, Female, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Index Mod: <1, Negative	
	Service Delivery Point (Community) Index Mod: <1, Positive	
	Service Delivery Point (Community) Index Mod: 1-9, Negative	
	Service Delivery Point (Community) Index Mod: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Male, Negative	



	Service Delivery Point Agg Age (Community) Index Mod: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) ANC: <1, Negative	
	Service Delivery Point (Facility) ANC: <1, Positive	
	Service Delivery Point (Facility) ANC: 10-14, Negative	
	Service Delivery Point (Facility) ANC: 10-14, Positive	



	Service Delivery Point (Facility) ANC: 15-19, Negative	
	Service Delivery Point (Facility) ANC: 15-19, Positive	
	Service Delivery Point (Facility) ANC: 1-9, Negative	
	Service Delivery Point (Facility) ANC: 1-9, Positive	
	Service Delivery Point (Facility) ANC: 20-24, Negative	
	Service Delivery Point (Facility) ANC: 20-24, Positive	
	Service Delivery Point (Facility) ANC: 25-49, Negative	
	Service Delivery Point (Facility) ANC: 25-49, Positive	
	Service Delivery Point (Facility) ANC: 50+, Negative	
	Service Delivery Point (Facility) ANC: 50+, Positive	
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point Agg Age (Facility) ANC: <15, Negative	
	Service Delivery Point Agg Age (Facility) ANC: <15, Positive	
	Service Delivery Point Agg Age (Facility) ANC: 15+, Negative	
	Service Delivery Point Agg Age (Facility) ANC: 15+, Positive	
	Service Delivery Point Agg Age (Facility) ANC: Unknown Age,	



	Negative	
	Service Delivery Point Agg Age (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	



	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VCT: <1, Negative	
	Service Delivery Point (Facility) VCT: <1, Positive	
	Service Delivery Point (Facility) VCT: 1-9, Negative	
	Service Delivery Point (Facility) VCT: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) VCT: <15, Female,	



	Positive	
	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	10,080
	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	459
	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	20,126
	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	1,191
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	
	Service Delivery Point (Community)	



	VCT Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	
	Service Delivery Point (Community)	



	VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: <1, Negative	
	Service Delivery Point (Community) VCT Mod: <1, Positive	
	Service Delivery Point (Community) VCT Mod: 1-9, Negative	
	Service Delivery Point (Community) VCT Mod: 1-9, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Female, Negative	
	Service Delivery Point Agg Age	



	(Community) VCT Mod: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	90 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,025
	Total number of registered new and relapsed TB cases, during the reporting period.	2,250
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB	74



	cases, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	575
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	187
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,414
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	518
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,272
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	67
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	168
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB)	



	cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received	182,347



	their test results during the past 12 months	
	By Test Result: Positive	6,445
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Male,	



	Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community)	



	Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Homebased testing: <1, Negative	
	Service Delivery Point (Community) Homebased testing: <1, Positive	
	Service Delivery Point (Community) Homebased testing: 1-9, Negative	
	Service Delivery Point (Community) Homebased testing: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	
	Service Delivery Point by Agg Age	



	(Community) Homebased testing: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) by Aggregated Age: Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	
	Service Delivery Point (Facility)	



	Inpatient: 20-24, Female, Positive	
	Service Delivery Point (Facility)	
	Inpatient: 20-24, Male, Negative	
	Service Delivery Point (Facility)	
	Inpatient: 20-24, Male, Positive	
	Service Delivery Point (Facility)	
	Inpatient: 25-49, Female, Negative	
	Service Delivery Point (Facility)	
	Inpatient: 25-49, Female, Positive	
	Service Delivery Point (Facility)	
	Inpatient: 25-49, Male, Negative	
	Service Delivery Point (Facility)	
	Inpatient: 25-49, Male, Positive	
	Service Delivery Point (Facility)	
	Inpatient: 50+, Female, Negative	
	Service Delivery Point (Facility)	
	Inpatient: 50+, Female, Positive	
	Service Delivery Point (Facility)	
	Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility)	
	Inpatient: 50+, Male, Positive	
	Service Delivery Point (Facility)	
	Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point (Facility)	
	Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point (Facility)	
	Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point (Facility)	
	Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)	



	Inpatient: <1, Negative	
	Service Delivery Point (Facility) Inpatient: <1, Positive	
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age	



	(Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	



	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	



	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: <1, Negative	
	Service Delivery Point (Community) Mobile Testing: <1, Positive	
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	



	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	
	Service Delivery Point (Facility)	



	Other PITC: 15-19, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	



	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: <1, Negative	
	Service Delivery Point (Facility) Other PITC: <1, Positive	
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	



	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	
	Service Delivery Point (Community) Other: 10-14, Female, Positive	
	Service Delivery Point (Community) Other: 10-14, Male, Negative	
	Service Delivery Point (Community) Other: 10-14, Male, Positive	
	Service Delivery Point (Community) Other: 15-19, Female, Negative	
	Service Delivery Point (Community) Other: 15-19, Female, Positive	
	Service Delivery Point (Community) Other: 15-19, Male, Negative	
	Service Delivery Point (Community) Other: 15-19, Male, Positive	



	Service Delivery Point (Community) Other: 20-24, Female, Negative	
	Service Delivery Point (Community) Other: 20-24, Female, Positive	
	Service Delivery Point (Community) Other: 20-24, Male, Negative	
	Service Delivery Point (Community) Other: 20-24, Male, Positive	
	Service Delivery Point (Community) Other: 25-49, Female, Negative	
	Service Delivery Point (Community) Other: 25-49, Female, Positive	
	Service Delivery Point (Community) Other: 25-49, Male, Negative	
	Service Delivery Point (Community) Other: 25-49, Male, Positive	
	Service Delivery Point (Community) Other: 50+, Female, Negative	
	Service Delivery Point (Community) Other: 50+, Female, Positive	
	Service Delivery Point (Community) Other: 50+, Male, Negative	
	Service Delivery Point (Community) Other: 50+, Male, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point (Community)	



	Other: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: <1, Negative	
	Service Delivery Point (Community) Other: <1, Positive	
	Service Delivery Point (Community) Other: 1-9, Negative	
	Service Delivery Point (Community) Other: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	35,246
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	622
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	59,642
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	2,463
	Service Delivery Point by Agg Age	



	(Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Pediatric : <5 Negative	
	Service Delivery Point (Facility) Pediatric : <5 Positive	
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	
	Service Delivery Point (Facility) TB:	



	20-24, Female, Positive	
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	
	Service Delivery Point (Facility) TB: 25-49, Female, Negative	
	Service Delivery Point (Facility) TB: 25-49, Female, Positive	
	Service Delivery Point (Facility) TB: 25-49, Male, Negative	
	Service Delivery Point (Facility) TB: 25-49, Male, Positive	
	Service Delivery Point (Facility) TB: 50+, Female, Negative	
	Service Delivery Point (Facility) TB: 50+, Female, Positive	
	Service Delivery Point (Facility) TB: 50+, Male, Negative	
	Service Delivery Point (Facility) TB: 50+, Male, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) TB: <1, Negative	
	Service Delivery Point (Facility) TB: <1, Positive	
	Service Delivery Point (Facility) TB:	



	1-9, Negative	
	Service Delivery Point (Facility) TB: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	27
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	101
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)	



	VMMC: <1, Negative	
	Service Delivery Point (Facility) VMMC: <1, Positive	
	Service Delivery Point (Facility) VMMC: 10-14, Negative	
	Service Delivery Point (Facility) VMMC: 10-14, Positive	
	Service Delivery Point (Facility) VMMC: 15-19, Negative	
	Service Delivery Point (Facility) VMMC: 15-19, Positive	
	Service Delivery Point (Facility) VMMC: 1-9, Negative	
	Service Delivery Point (Facility) VMMC: 1-9, Positive	
	Service Delivery Point (Facility) VMMC: 20-24, Negative	
	Service Delivery Point (Facility) VMMC: 20-24, Positive	
	Service Delivery Point (Facility) VMMC: 25-49, Negative	
	Service Delivery Point (Facility) VMMC: 25-49, Positive	
	Service Delivery Point (Facility) VMMC: 50+, Negative	
	Service Delivery Point (Facility) VMMC: 50+, Positive	
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility) VMMC: <15, Negative	
	Service Delivery Point by Agg Age	



	(Facility) VMMC: <15, Positive	
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	
	Service Delivery Point (Facility)	



	Index: 20-24, Male, Positive	
	Service Delivery Point (Facility) Index: 25-49, Female, Negative	
	Service Delivery Point (Facility) Index: 25-49, Female, Positive	
	Service Delivery Point (Facility) Index: 25-49, Male, Negative	
	Service Delivery Point (Facility) Index: 25-49, Male, Positive	
	Service Delivery Point (Facility) Index: 50+, Female, Negative	
	Service Delivery Point (Facility) Index: 50+, Female, Positive	
	Service Delivery Point (Facility) Index: 50+, Male, Negative	
	Service Delivery Point (Facility) Index: 50+, Male, Positive	
	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Index: <1, Negative	
	Service Delivery Point (Facility) Index: <1, Positive	
	Service Delivery Point (Facility)	



	Index: 1-9, Negative	
	Service Delivery Point (Facility) Index: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age	



	(Facility) Index: Unknown Age, Male, Positive	
	By Key Population: FSW, Negative	
	By Key Population: FSW, Positive	
	By Key Population: MSM, Negative	
	By Key Population: MSM, Positive	
	By Key Population: People in prisons and other enclosed settings, Negative	
	By Key Population: People in prisons and other enclosed settings, Positive	
	By Key Population: PWID, Negative	
	By Key Population: PWID, Positive	
	By Key Population: TG, Negative	
	By Key Population: TG, Positive	
	Service Delivery Point (Facility) Malnutrition: Negative	
	Service Delivery Point (Facility) Malnutrition: Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	
	Service Delivery Point (Community)	



	Index Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	



	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Index Mod: <1, Negative	
	Service Delivery Point (Community) Index Mod: <1, Positive	
	Service Delivery Point (Community) Index Mod: 1-9, Negative	
	Service Delivery Point (Community) Index Mod: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	



	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) ANC: <1, Negative	
	Service Delivery Point (Facility) ANC: <1, Positive	
	Service Delivery Point (Facility) ANC: 10-14, Negative	
	Service Delivery Point (Facility) ANC: 10-14, Positive	
	Service Delivery Point (Facility) ANC: 15-19, Negative	
	Service Delivery Point (Facility) ANC: 15-19, Positive	
	Service Delivery Point (Facility) ANC: 1-9, Negative	
	Service Delivery Point (Facility) ANC: 1-9, Positive	



	Service Delivery Point (Facility) ANC: 20-24, Negative	
	Service Delivery Point (Facility) ANC: 20-24, Positive	
	Service Delivery Point (Facility) ANC: 25-49, Negative	
	Service Delivery Point (Facility) ANC: 25-49, Positive	
	Service Delivery Point (Facility) ANC: 50+, Negative	
	Service Delivery Point (Facility) ANC: 50+, Positive	
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	
	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	



	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	



	Service Delivery Point (Facility) VCT: 50+, Male, Positive	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) VCT:	
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VCT: <1, Negative	
	Service Delivery Point (Facility) VCT: <1, Positive	
	Service Delivery Point (Facility) VCT: 1-9, Negative	
	Service Delivery Point (Facility) VCT: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	32,398
	Service Delivery Point by Agg Age	860



	(Facility) VCT: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	48,504
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	2,484
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	



	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community)	



	VCT Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: <1, Negative	
	Service Delivery Point (Community) VCT Mod: <1, Positive	
	Service Delivery Point (Community) VCT Mod: 1-9, Negative	
	Service Delivery Point (Community) VCT Mod: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Positive	
	Service Delivery Point by Agg Age	



	(Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	90 %
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	84
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	93
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	



	ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	22



	the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	52
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	<p>Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Denominator: The number of</p>	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB	24



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	58
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	8
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	80 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,734
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB	3,413



	preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
	By Age/Sex (Denominator): <15, Female	43
	By Age/Sex (Denominator): <15, Male	46
	By Age/Sex (Denominator): 15+, Female	1,134
	By Age/Sex (Denominator): 15+, Male	2,190
	By Therapy type (Denominator): 6-12 Month IPT	
	By Therapy type (Denominator): Alternative Regimen	
	By Therapy type (Denominator): Continuous IPT	
	By Age/Sex (Numerator): <15, Female	35
	By Age/Sex (Numerator): <15, Male	36
	By Age/Sex (Numerator): 15+, Female	918
	By Age/Sex (Numerator): 15+, Male	1,745
	By Therapy type (Numerator): 6-12 Month IPT	
	By Therapy type (Numerator): Alternative Regimen	
	By Therapy type (Numerator): Continuous IPT	



TB_PREV_TA	TB_PREV_TA TB_PREV_TA	80 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3,607
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,511
	By Age/Sex (Denominator): <15, Female	82
	By Age/Sex (Denominator): <15, Male	82
	By Age/Sex (Denominator): 15+, Female	1,541
	By Age/Sex (Denominator): 15+, Male	2,806
	By Therapy type (Denominator): 6-12 Month IPT	
	By Therapy type (Denominator): Alternative Regimen	
	By Therapy type (Denominator): Continuous IPT	
	By Age/Sex (Numerator): <15, Female	65
	By Age/Sex (Numerator): <15, Male	63



	By Age/Sex (Numerator): 15+, Female	1,235
	By Age/Sex (Numerator): 15+, Male	2,244
	By Therapy type (Numerator): 6-12 Month IPT	
	By Therapy type (Numerator): Alternative Regimen	
	By Therapy type (Numerator): Continuous IPT	
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	2 %
	Number of ART patients who were started on TB treatment during the reporting period.	805
	Number of ART patients who were screened for TB at least once during the reporting period	40,480
	Numerator: By Aggregated Age/Sex: <15, Female	5
	Numerator: By Aggregated Age/Sex: <15, Male	7
	Numerator: By Aggregated Age/Sex: 15+, Female	259
	Numerator: By Aggregated Age/Sex: 15+, Male	534
	Denominator: By Aggregated Age/Sex: <15, Female	659
	Denominator: By Aggregated Age/Sex: <15, Male	727
	Denominator: By Aggregated Age/Sex: 15+, Female	13,475
	Denominator: By Aggregated	25,619



	Age/Sex:15+, Male	
	Denominator: By Screen Result: Negative	
	Denominator: By Screen Result: Positive	
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	
TX_TB_TA	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	2 %
	Number of ART patients who were started on TB treatment during the reporting period.	1,077
	Number of ART patients who were screened for TB at least once during the reporting period	49,113
	Numerator: By Aggregated Age/Sex: <15, Female	26
	Numerator: By Aggregated Age/Sex: <15, Male	26
	Numerator: By Aggregated Age/Sex: 15+, Female	360
	Numerator: By Aggregated Age/Sex: 15+, Male	665



	Denominator: By Aggregated Age/Sex: <15, Female	1,224
	Denominator: By Aggregated Age/Sex: <15, Male	1,219
	Denominator: By Aggregated Age/Sex: 15+, Female	16,644
	Denominator: By Aggregated Age/Sex: 15+, Male	30,026
	Denominator: By Screen Result: Negative	
	Denominator: By Screen Result: Positive	
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	342
	Number of HIV- positive pregnant women identified during the reporting period (include known	



	HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	
	Sum of Infant Age disaggregates	
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	5
	Number of infants with a positive virological test result within 12 months of birth	
	Unknown, <= 2 months	
	Unknown, 2 - 12 months	
	Number of infants with a negative virological test result within 2 months of birth	212
	Number of infants with a positive virological test result between 2 and 12 months of birth	12
	Number of infants with a negative virological test result between 2 and 12 months of birth	113
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	780



	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	
	Sum of Infant Age disaggregates	
	By infants with a positive virologic test result within 12 months of birth	
	Unknown, <= 2 months	
	Unknown, 2 - 12 months	
	Number of infants with a positive virological test result within 2 months of birth	9
	Number of infants with a negative virological test result within 2 months of birth	631
	Number of infants with a positive virological test result between 2 and 12 months of birth	28
	Number of infants with a negative virological test result between 2 and 12 months of birth	112
	Number of infants with a positive virological test result within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	42,589
	Age/Sex: 15-19 Male	



	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	766
	Aggregated Age/Sex: 15+ Male	26,954
	Aggregated Age/Sex: <15 Female	694
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	14,175
	Sum of Aggregated Age/Sex <15	1,460
	Sum of Aggregated Age/Sex 15+	41,129
	Sum of Aggregated Age/Sex disaggregates	42,589
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	35,312
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	



	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	1,117
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	20,997
	Aggregated Age/Sex: <15 Female	1,093
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	12,105
	Sum of Aggregated Age/Sex <15	2,210
	Sum of Aggregated Age/Sex 15+	33,102
	Sum of Aggregated Age/Sex disaggregates	35,312
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral	4,269



	therapy (ART)	
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	54
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	2,733
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	53
	Aggregated Grouping by Age/Sex: 15+ Female	1,429
	Pregnancy status	
	Breastfeeding status	
	FSW	
	MSM	
	People in prisons and other	



	enclosed settings	
	TG	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	By Key populations: People who inject drugs (PWID)	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,856
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
Aggregated Grouping by Age: <1		
Aggregated Grouping by Age: <1 Male		
Aggregated Grouping by Age/Sex: <15 Male	85	



	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	2,351
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	79
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,341
	Sum of Aggregated Age/Sex disaggregates	3,856
	Pregnancy status	
	Breastfeeding status	
	FSW	
	MSM	
	People in prisons and other enclosed settings	
	TG	
	By Key populations: People who inject drugs (PWID)	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	91 %
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records	33,279



	and /or supporting laboratory results within the past 12 months.	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	36,578
	Numerator: Indication: Routine	33,279
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication:	



	15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by	



	Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	613
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	20,996
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	556
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	11,114
	Denominator: Indication: Routine	36,578
	Denominator: Indication: Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by	



	Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by	



	Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	676
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	23,059
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	618
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	12,225
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex:	



	15+ Female	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	
	<15, Undocumented Test Indication, Male	
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	
	15+, Undocumented Test Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	



	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	
	<15, Undocumented Test Indication, Male	
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	
	15+, Undocumented Test Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	



	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	90 %
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	26,847
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	29,786
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	



	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	



Numerator: Age/Sex by Indication: 50+ Male Targeted	
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	825
Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	843
Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	9,269
Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	15,910
Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
Numerator: Indication: Routine	26,847
Numerator: Indication: Targeted	
Numerator: Preg/BF by Indication: Breastfeeding Routine	
Numerator: Preg/BF by Indication: Breastfeeding Targeted	
Numerator: Preg/BF by Indication: Pregnant Routine	
Numerator: Preg/BF by Indication: Pregnant Targeted	
Denominator: Indication: Routine	29,786
Denominator: Indication: Targeted	
Denominator: Age/Sex by Indication: <1 Routine	
Denominator: Age/Sex by Indication: <1 Targeted	



	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	



	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	905
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	922
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	10,302
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	17,657
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	



	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	
	<15, Undocumented Test Indication, Male	
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	
	15+, Undocumented Test Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	



	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	
	<15, Undocumented Test Indication, Male	
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	
	15+, Undocumented Test Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	



	Unknown Age, Routine, Male	
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	89 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,062
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,539
	Age/Sex: <1 (Numerator: Number of adults and children who are still	



	alive and on treatment at 12 months after initiating ART	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	



	initiating ART	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	51



	initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,622
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	47
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,342
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	55
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,927
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	52



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,505
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	91 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,528
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,884
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who	



	are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and	



	children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at	



	12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	95
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,138
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and	89



	children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,206
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	103
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,355
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	96
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	1,330

Approved



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	--	--



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9972	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9976	Ministry of Health, Vietnam	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,068,269
9977	National Institute for Hygiene and Epidemiology	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	562,113
9998	Pasteur Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0



10000	Harvard Medical School of AIDS Initiative in Vietnam	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,451,997
10118	Vietnam Administration for Medical Sciences	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	153,782
10831	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	108,000
10832	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	123,092
11609	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of East Asian and Pacific Affairs	GHP-State	0
12341	Vietnam Nurses' Association	Implementing Agency	U.S. Department of Defense	GHP-State	0
13007	National Tuberculosis	Host Country Government	U.S. Department of Health and	GHP-State	190,760



	Program	Agency	Human Services/Centers for Disease Control and Prevention		
13147	New York AIDS Institute	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
13234	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	0
13779	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	230,169
14156	The Center for Community Health Research and Development	NGO	U.S. Agency for International Development	GHP-State	164,165
14336	Hanoi Medical University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	340,000
16803	Program for Appropriate Technology in	NGO	U.S. Agency for International Development	GHP-State	1,650,000



	Health				
17371	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	532,363
18149	Center for Community Health Promotion	NGO	U.S. Department of Defense	GHP-State	0
18172	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,879,314
18173	Center for Promotion of Quality of Life	NGO	U.S. Agency for International Development	GHP-State	497,206
18194	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	8,968,876
18271	Ho Chi Minh City Department of Health	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,243,541
18541	TBD	TBD	Redacted	Redacted	Redacted
18616	CENTER FOR COMMUNITY HEALTH RESEARCH AND DEVELOPMENT	NGO	U.S. Agency for International Development	GHP-State	335,502
18618	TBD	TBD	Redacted	Redacted	Redacted
18619	TBD	TBD	Redacted	Redacted	Redacted
18620	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 9972	Mechanism Name: APHL LAB
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 19,606	
Total All Funding Sources and Applied Pipeline Amount: 19,606	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	9972		
Mechanism Name:	APHL LAB		
Prime Partner Name:	Association of Public Health Laboratories		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9976	Mechanism Name: Vietnam Administration for HIV/AIDS Control (VAAC)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Vietnam	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 5,068,269	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,806,333	
Total All Funding Sources and Applied Pipeline Amount: 6,874,602	
Funding Source	Funding Amount
GHP-State	5,068,269

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	150,000
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Gender: Gender Equality	100,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Human Resources for Health	500,000



Budget Code Information

Mechanism ID: 9976			
Mechanism Name: Vietnam Administration for HIV/AIDS Control (VAAC)			
Prime Partner Name: Ministry of Health, Vietnam			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	129,592	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	200,958	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	66,861	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	65,889	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,427,873	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	120,291	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	90,179	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,684,082	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	82,544	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
KP_MAT_TA	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	5,620
KP_MAT_TA	Sex: Female	77
KP_MAT_TA	Sex: Male	5,543
KP_MAT_TA	Sum of Sex Disaggregates	5,620
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	20,539
PP_PREV_DSD	Age/sex: 20-24 Male	491
PP_PREV_DSD	Age/sex: 25-49 Male	1,953
PP_PREV_DSD	Age/sex: 15-19 Female	979
PP_PREV_DSD	Age/sex: 20-24 Female	1,793
PP_PREV_DSD	Age/sex: 25-49 Female	15,323
PP_PREV_DSD	Sum of Age/Sex disaggregates	20,539
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	23,304
KP_PREV_DSD	By key population type: Men who have sex with men	2,742



	who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,204
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	17,381
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	977
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	84,404
HTC_TST_DSD	By Test Result: Positive	2,443
HTC_TST_DSD	Sum of Test Result disaggregates	2,443
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	19,249
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	282
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	25,252
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	655
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	14,678
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+,	473



	Female, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	22,798
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	1,017
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	23,717
HTC_TST_TA	By Test Result: Positive	1,290
HTC_TST_TA	Sum of Test Result disaggregates	1,290
HTC_TST_TA	Service Delivery Point Agg Age (Community) Other: 15+, Female, Negative	558
HTC_TST_TA	Service Delivery Point Agg Age (Community) Other: 15+, Female, Positive	12
HTC_TST_TA	Service Delivery Point Agg Age (Community) Other: 15+, Male, Negative	1,148
HTC_TST_TA	Service Delivery Point Agg Age (Community) Other: 15+, Male, Positive	48
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	6,163
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	346
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	14,580
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	862
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	271
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	5
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	163
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	11



PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	92
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	245
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	3
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	178
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	5
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	59
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	16,288
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	570
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	9,467
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	476
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,775
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,046
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	15,242
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	16,288
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	11,884
TX_CURR_TA	Aggregated Age/Sex: <15 Male	459
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,497
TX_CURR_TA	Aggregated Age/Sex: <15 Female	457
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	4,471
TX_CURR_TA	Sum of Aggregated Age/Sex <15	916
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	10,968
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	11,884
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,534
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	36



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	916
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	31
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	551
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,534
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,199
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	39
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	671
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	40
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	449
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,199
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	13,193
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14,661
TX_PVLS_DSD	Numerator: Indication: Routine	13,193
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	462
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	7,668
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	386
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,677
TX_PVLS_DSD	Denominator: Indication: Routine	14,661
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	513
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	8,523
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	430



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	5,195
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	9,626
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	10,697
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	370
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	373
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,618
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,265
TX_PVLS_TA	Numerator: Indication: Routine	9,626
TX_PVLS_TA	Denominator: Indication: Routine	10,697
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	412
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	412
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,025
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,848
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,273
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,383
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of	31



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	763
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	453
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	824
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	498
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	995
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	1,079



	period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	555
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	33
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	373
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	36
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	603
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	406
TB_PREV_DSD	The number of ART patients who completed a course	983



	of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,223
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	25
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	31
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	435
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	732
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	19
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	25
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	354
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	585
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	765
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	962
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	33
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	32
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	362
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	535
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	23



TB_PREV_TA	By Age/Sex (Numerator): <15, Male	26
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	288
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	428
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	145
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	15,473
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	3
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	4
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	54
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	84
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	451
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	543
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	5,484
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	8,995
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	244
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	11,291
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	9
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	9
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	93
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	133
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	434
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	437
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	4,246
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	6,174

Implementing Mechanism Details

Mechanism ID: 9977	Mechanism Name: NIHE Follow on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Institute for Hygiene and Epidemiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 562,113	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 562,113	
Funding Source	Funding Amount
GHP-State	562,113

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9977			
Mechanism Name: NIHE Follow on			
Prime Partner Name: National Institute for Hygiene and Epidemiology			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	41,056	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	211,057	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	310,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9998	Mechanism Name: PI
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Pasteur Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 413,522	
Total All Funding Sources and Applied Pipeline Amount: 413,522	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	9998		
Mechanism Name:	PI		
Prime Partner Name:	Pasteur Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10000	Mechanism Name: HAIVN
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Harvard Medical School of AIDS Initiative in Vietnam	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,451,997	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,451,997	
Funding Source	Funding Amount
GHP-State	1,451,997

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10000
Mechanism Name:	HAIVN
Prime Partner Name:	Harvard Medical School of AIDS Initiative in Vietnam



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	34,300	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	48,020	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	6,860	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	86,333	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,176,432	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	100,052	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	22,457
TX_CURR_TA	Aggregated Age/Sex: <15 Male	459
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	13,589
TX_CURR_TA	Aggregated Age/Sex: <15 Female	409
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	8,000
TX_CURR_TA	Sum of Aggregated Age/Sex <15	868



TX_CURR_TA	Sum of Aggregated Age/Sex 15+	21,589
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	22,457
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,777
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	53
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,699
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	46
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	979
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	2,777
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	17,885
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	19,875
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	325
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	365
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	6,380
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,815
TX_PVLS_TA	Numerator: Indication: Routine	17,885
TX_PVLS_TA	Denominator: Indication: Routine	19,875
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	359
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	402
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	7,105
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	12,009



TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,306
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,502
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,412
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	811
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	48
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,530
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	40
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	884



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,779
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,222
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	38
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	42
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	785
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	1,357
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	29
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	35
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	625
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	1,090
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	414
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	21,336
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	7
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	7
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	152
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	248
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	386
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	435
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	7,606
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	12,909



Implementing Mechanism Details

Mechanism ID: 10118	Mechanism Name: Department of Medical Administration
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Vietnam Administration for Medical Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 153,782	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 153,782	
Funding Source	Funding Amount
GHP-State	153,782

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 10118			
Mechanism Name: Department of Medical Administration			
Prime Partner Name: Vietnam Administration for Medical Sciences			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	146,890	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,892	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10831	Mechanism Name: CLSI LAB
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 108,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 108,000	
Funding Source	Funding Amount
GHP-State	108,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	10831		
Mechanism Name:	CLSI LAB		
Prime Partner Name:	Clinical and Laboratory Standards Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	108,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10832	Mechanism Name: ASCP LAB
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 123,092	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 86,485	
Total All Funding Sources and Applied Pipeline Amount: 209,577	
Funding Source	Funding Amount
GHP-State	123,092

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 10832			
Mechanism Name: ASCP LAB			
Prime Partner Name: American Society of Clinical Pathology			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	63,092	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	60,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11609	Mechanism Name: Ambassador's Fund for HIV/AIDS Public Diplomacy
Funding Agency: State/EAP	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 50,000	
Total All Funding Sources and Applied Pipeline Amount: 50,000	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11609			
Mechanism Name: Ambassador's Fund for HIV/AIDS Public Diplomacy			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12341	Mechanism Name: VNA
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Vietnam Nurses' Association	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: DOD

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 517,500	
Total All Funding Sources and Applied Pipeline Amount: 517,500	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12341			
Mechanism Name: VNA			
Prime Partner Name: Vietnam Nurses' Association			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13007	Mechanism Name: NTP Follow on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Tuberculosis Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 190,760	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 190,760	
Funding Source	Funding Amount
GHP-State	190,760

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13007			
Mechanism Name: NTP Follow on			
Prime Partner Name: National Tuberculosis Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	165,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	8,587	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	8,586	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	8,587	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13147		Mechanism Name: HEATHQUAL	
Funding Agency: HHS/HRSA		Procurement Type: Cooperative Agreement	
Prime Partner Name: New York AIDS Institute			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	
Total All Funding Sources: 0		Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 58,000			
Total All Funding Sources and Applied Pipeline Amount: 58,000			
Funding Source		Funding Amount	
GHP-State		0	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13147			
Mechanism Name: HEATHQUAL			
Prime Partner Name: New York AIDS Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13234	Mechanism Name: Challenge TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 438,852	
Total All Funding Sources and Applied Pipeline Amount: 438,852	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13234



Mechanism Name:	Challenge TB		
Prime Partner Name:	KNCV Tuberculosis Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	128
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	27
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	101
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,913
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	63
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	159
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	490
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	1,201
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,025
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,250
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases,	74



	during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	575
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	187
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,414
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	518
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,272
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	67
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	168
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	84
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	93
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	52



	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	24
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	58
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	8
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,728
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting	2,161



	period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	24
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	20
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	726
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	1,391
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	22
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	13
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	584
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	1,109
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	567
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	24,790
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	4
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	3
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	187
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	373
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	307
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	250
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	8,367
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	15,866

Implementing Mechanism Details

Mechanism ID: 13779	Mechanism Name: WHO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 230,169	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 230,169	
Funding Source	Funding Amount
GHP-State	230,169

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13779		
Mechanism Name:	WHO		
Prime Partner Name:	World Health Organization		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	80,169	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14156	Mechanism Name: Strengthen In-Country Strategic Information Capacity for Sustainable HIV Response
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: The Center for Community Health Research and Development	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 164,165	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 35,835	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	164,165

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14156		
Mechanism Name:	Strengthen In-Country Strategic Information Capacity for Sustainable		
Prime Partner Name:	HIV Response		
	The Center for Community Health Research and Development		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	164,165	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 14336	Mechanism Name: HMU follow on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hanoi Medical University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 340,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 340,000	
Funding Source	Funding Amount
GHP-State	340,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14336		
Mechanism Name:	HMU follow on		
Prime Partner Name:	Hanoi Medical University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	245,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	65,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16803	Mechanism Name: Healthy Markets
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,650,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,650,000	
Funding Source	Funding Amount
GHP-State	1,650,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 16803			
Mechanism Name: Healthy Markets			
Prime Partner Name: Program for Appropriate Technology in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	270,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	792,430	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	567,570	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	20,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,700
PrEP_NEW_DSD	Male 20-24	1,070
PrEP_NEW_DSD	Male 25-49	380
PrEP_NEW_DSD	Female 20-24	150
PrEP_NEW_DSD	Female 25-49	100
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	3,867



	standards required	
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	314
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,443
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	17
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	93
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,500
KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,500
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,935
HTC_TST_DSD	By Test Result: Positive	1,438
HTC_TST_DSD	Sum of Test Result disaggregates	1,438



HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	13,624
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	226
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	25,873
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	1,212

Implementing Mechanism Details

Mechanism ID: 17371	Mechanism Name: Health Finance & Governance (HFG)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 532,363	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 167,637	
Total All Funding Sources and Applied Pipeline Amount: 700,000	
Funding Source	Funding Amount
GHP-State	532,363

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17371
----------------------	--------------



Mechanism Name:	Health Finance & Governance (HFG)		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	532,363	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18149	Mechanism Name: CHP – HIV/AIDS Prevention
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Center for Community Health Promotion	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 610,599	
Total All Funding Sources and Applied Pipeline Amount: 610,599	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 18149			
Mechanism Name: CHP – HIV/AIDS Prevention			
Prime Partner Name: Center for Community Health Promotion			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	50,000
PP_PREV_DSD	Age/sex: 20-24 Male	50,000
PP_PREV_DSD	Sum of Age/Sex disaggregates	50,000
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	29,620
HTC_TST_TA	By Test Result: Positive	106
HTC_TST_TA	Sum of Test Result disaggregates	106
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	9,424
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC:	20



	15+, Female, Positive	
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	20,090
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	86
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	371
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	260
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	110
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	370
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	371
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	187
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	131
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	56
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	187
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	187
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	242
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	334
TX_PVLS_DSD	Numerator: Indication: Routine	242
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	170
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	72
TX_PVLS_DSD	Denominator: Indication: Routine	334
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	234



	Male Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	99
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	87
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	168
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	26
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	61
TX_PVLS_TA	Numerator: Indication: Routine	87
TX_PVLS_TA	Denominator: Indication: Routine	168
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	50
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	118
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	7
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	371
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	2
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	5
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	110
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	260
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	4
TX_TB_TA	Number of ART patients who were screened for TB at	187



	least once during the reporting period	
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	1
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	3
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	56
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	131

Implementing Mechanism Details

Mechanism ID: 18172	Mechanism Name: Sustainable HIV Response from Technical Assistance (SHIFT) Project	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,879,314	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 4,525,148	
Total All Funding Sources and Applied Pipeline Amount: 6,404,462	
Funding Source	Funding Amount
GHP-State	1,879,314

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18172		
Mechanism Name:	Sustainable HIV Response from Technical Assistance (SHIFT) Project		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	140,226	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	69,992	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	6,380	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	153,465	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	36,051	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	194,834	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	158,279	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	151,360	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	955,968	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	12,759	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
KP_MAT_TA	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	5,250
KP_MAT_TA	Sex: Female	109
KP_MAT_TA	Sex: Male	5,141
KP_MAT_TA	Sum of Sex Disaggregates	5,250
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,497
PP_PREV_DSD	Age/sex: 20-24 Male	15
PP_PREV_DSD	Age/sex: 25-49 Male	60
PP_PREV_DSD	Age/sex: 15-19 Female	75
PP_PREV_DSD	Age/sex: 20-24 Female	150
PP_PREV_DSD	Age/sex: 25-49 Female	6,197
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,497
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	13,052
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	713
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key	4,037



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	38
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	212
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	556
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,956
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	540
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	37,067
HTC_TST_DSD	By Test Result: Positive	1,356
HTC_TST_DSD	Sum of Test Result disaggregates	1,356
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	373



HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	23
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	2,447
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	157
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	14,348
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	267
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	18,543
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	909
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,600
HTC_TST_TA	By Test Result: Positive	236
HTC_TST_TA	Sum of Test Result disaggregates	236
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	3,049
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	80
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	3,315
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	156
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	53
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	32
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	1
PMTCT_EID_DSD	Number of infants with a negative virological test result	20



	between 2 and 12 months of birth	
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	26
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	6
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	1
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	19
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	16,370
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	169
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	10,605
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	195
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,401
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	364
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	16,006
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	16,370
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	9,722
TX_CURR_TA	Aggregated Age/Sex: <15 Male	97
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,098
TX_CURR_TA	Aggregated Age/Sex: <15 Female	127
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	3,400
TX_CURR_TA	Sum of Aggregated Age/Sex <15	224
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	9,498
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	9,722
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,777
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	16
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,150
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	20
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	591



TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,777
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	921
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	8
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	580
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	10
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	323
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	921
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	12,731
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	13,935
TX_PVLS_DSD	Numerator: Indication: Routine	12,731
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	131
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	8,230
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	154
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,216
TX_PVLS_DSD	Denominator: Indication: Routine	13,935
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	142
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	9,004
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	170
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,619
TX_PVLS_TA	Number of adults and pediatric patients on ART with	7,039



	suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,761
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	85
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	61
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,494
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,399
TX_PVLS_TA	Numerator: Indication: Routine	7,039
TX_PVLS_TA	Denominator: Indication: Routine	7,761
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	96
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	69
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,749
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,847
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,758
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,985
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of	1,141



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	581
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,288
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	656
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	883
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	999
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of	7



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	561
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	305
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	639
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	342
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,137



TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,423
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	16
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	13
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	471
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	923
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	14
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	9
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	380
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	734
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	591
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	738
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	8
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	7
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	255
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	468
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	8
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	4
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	204
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	375



TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	334
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	15,553
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	2
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	2
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	106
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	224
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	186
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	158
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	5,135
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	10,074
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	233
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	9,237
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	2
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	81
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	149
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	121
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	92
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	3,232
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	5,792

Implementing Mechanism Details

Mechanism ID: 18173	Mechanism Name: USAID Enhanced Community HIV Link- Southern Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Promotion of Quality of Life	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 497,206	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 497,206	
Funding Source	Funding Amount
GHP-State	497,206

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18173			
Mechanism Name: USAID Enhanced Community HIV Link- Southern Project			
Prime Partner Name: Center for Promotion of Quality of Life			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	16,628	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	480,578	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	14,800



	standards required	
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,109
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,952
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	111
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	628

Implementing Mechanism Details

Mechanism ID: 18194	Mechanism Name: Global Health Supply Chain Program (GHSCP)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 8,968,876	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 8,968,876	



Funding Source	Funding Amount
GHP-State	8,968,876

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18194			
Mechanism Name: Global Health Supply Chain Program (GHSCP)			
Prime Partner Name: Global Health Supply Chain Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	280,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	7,554,318	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,134,558	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18271	Mechanism Name: Department of Health HCMC
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ho Chi Minh City Department of Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 2,243,541	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 10,000	
Total All Funding Sources and Applied Pipeline Amount: 2,253,541	
Funding Source	Funding Amount
GHP-State	2,243,541

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	10,000
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID: 18271			
Mechanism Name: Department of Health HCMC			
Prime Partner Name: Ho Chi Minh City Department of Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	77,072	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	114,901	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	36,415	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	120,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	360,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	372,438	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	65,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	949,636	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	42,829	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a	3,500



	standardized HIV prevention intervention including the minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 15-19 Male	21
PP_PREV_DSD	Age/sex: 20-24 Male	157
PP_PREV_DSD	Age/sex: 25-49 Male	868
PP_PREV_DSD	Age/sex: 15-19 Female	75
PP_PREV_DSD	Age/sex: 20-24 Female	369
PP_PREV_DSD	Age/sex: 25-49 Female	2,010
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,500
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	400
PP_PREV_TA	Age/sex: 15-19 Male	4
PP_PREV_TA	Age/sex: 20-24 Male	16
PP_PREV_TA	Age/sex: 25-49 Male	100
PP_PREV_TA	Age/sex: 15-19 Female	8
PP_PREV_TA	Age/sex: 20-24 Female	44
PP_PREV_TA	Age/sex: 25-49 Female	228
PP_PREV_TA	Sum of Age/Sex disaggregates	400
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	13,499
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	427
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,422
KP_PREV_DSD	By key population type: Transgender who are sex	22



	workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	128
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,810
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,570
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,120
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,553
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	953
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV	100



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_TA	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	72
KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	404
KP_PREV_TA	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4
KP_PREV_TA	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	20
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,813
HTC_TST_DSD	By Test Result: Positive	1,208
HTC_TST_DSD	Sum of Test Result disaggregates	1,208
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	2,000
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	91
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	6,070
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	439



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	3,372
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	120
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	7,163
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	558
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,305
HTC_TST_TA	By Test Result: Positive	206
HTC_TST_TA	Sum of Test Result disaggregates	206
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	868
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	33
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	2,231
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	173
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	18
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	17
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	509
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	6
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	447
PMTCT_EID_TA	Number of infants with a positive virological test result	22



	between 2 and 12 months of birth	
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	34
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	9,560
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	27
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,622
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	22
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,889
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	49
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	9,511
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,560
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,664
TX_CURR_TA	Aggregated Age/Sex: <15 Male	434
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,171
TX_CURR_TA	Aggregated Age/Sex: <15 Female	418
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	641
TX_CURR_TA	Sum of Aggregated Age/Sex <15	852
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,812
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,664
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	958
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	667
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	287
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	958
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	145
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	18
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	72



TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	17
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	38
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	145
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	7,113
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,648
TX_PVLS_DSD	Numerator: Indication: Routine	7,113
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	20
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,928
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	16
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,149
TX_PVLS_DSD	Denominator: Indication: Routine	7,648
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	21
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,298
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	17
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,312
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,608
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	1,728



	and /or laboratory records in the past 12 months.	
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	302
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	314
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	364
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	628
TX_PVLS_TA	Numerator: Indication: Routine	1,608
TX_PVLS_TA	Denominator: Indication: Routine	1,728
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	324
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	337
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	392
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	675
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,031
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,171
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	718
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	308
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	815
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	351
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	327
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	371
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	165



TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	90
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	41
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	186
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	40
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	104
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	614
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting	767



	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	2
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	2
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	228
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	535
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	2
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	2
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	184
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	426
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	93
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	116
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	14
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	14
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	30
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	58
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	11
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	12
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	25
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	45
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	319
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	9,083
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	1



TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	97
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	221
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	21
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	26
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	2,746
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	6,290
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	88
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	2,532
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	13
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	14
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	20
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	41
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	398
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	413
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	609
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	1,112

Implementing Mechanism Details

Mechanism ID: 18541	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18616	Mechanism Name: USAID Enhanced Community HIV Link - Northern
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: CENTER FOR COMMUNITY HEALTH RESEARCH AND DEVELOPMENT	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 335,502	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 864,498	
Total All Funding Sources and Applied Pipeline Amount: 1,200,000	
Funding Source	Funding Amount
GHP-State	335,502

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18616		
Mechanism Name:	USAID Enhanced Community HIV Link - Northern		
Prime Partner Name:	CENTER FOR COMMUNITY HEALTH RESEARCH AND DEVELOPMENT		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	26,819	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	16,762	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	30,171	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	261,750	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,851
PP_PREV_DSD	Age/sex: 15-19 Male	30
PP_PREV_DSD	Age/sex: 20-24 Male	178
PP_PREV_DSD	Age/sex: 25-49 Male	234
PP_PREV_DSD	Age/sex: 15-19 Female	319
PP_PREV_DSD	Age/sex: 20-24 Female	642
PP_PREV_DSD	Age/sex: 25-49 Female	5,448
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,851
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,628
PP_PREV_TA	Age/sex: 15-19 Male	28
PP_PREV_TA	Age/sex: 20-24 Male	208
PP_PREV_TA	Age/sex: 25-49 Male	1,152
PP_PREV_TA	Age/sex: 15-19 Female	97
PP_PREV_TA	Age/sex: 20-24 Female	486
PP_PREV_TA	Age/sex: 25-49 Female	2,657
PP_PREV_TA	Sum of Age/Sex disaggregates	4,628
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,529
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	524
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	11,776



	the minimum standards required)	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	229
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,628
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,488
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	140

Implementing Mechanism Details

Mechanism ID: 18618	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18619	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18620	TBD: Yes
---------------------	----------

Approved



REDACTED



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		138,547		138,547	26,850	165,397
ICASS		335,101		335,101	244,320	579,421
Non-ICASS Administrative Costs		217,414		217,414	42,135	259,549
Staff Program Travel		315,825		315,825	61,206	377,031
USG Staff Salaries and Benefits - Internationally Recruited		721,183		721,183	139,764	860,947
USG Staff Salaries and Benefits - Locally Recruited		701,672		701,672	135,983	837,655
Total	0	2,429,742	0	2,429,742	650,258	3,080,000

U.S. Department of Defense

Agency Cost	GAP	GHP-State	GHP-USAID	Funding	Applied	Total All
-------------	-----	-----------	-----------	---------	---------	-----------



of Doing Business				Source Total	Pipeline	Funding Sources and Applied Pipeline Amount
Computers/IT Services		0		0	20,000	20,000
ICASS		0		0	110,000	110,000
Institutional Contractors				0	20,000	20,000
Management Meetings/Professional Development		0		0	40,000	40,000
Non-ICASS Administrative Costs		0		0	20,000	20,000
Staff Program Travel				0	100,000	100,000
USG Staff Salaries and Benefits - Locally Recruited		0		0	173,281	173,281
Total	0	0	0	0	483,281	483,281

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline
-------------------------------	-----	-----------	-----------	----------------------	------------------	--



						Amount
Capital Security Cost Sharing		0		0	479,893	479,893
Computers/IT Services		0		0	118,035	118,035
ICASS		0		0	1,326,845	1,326,845
Institutional Contractors				0	291,988	291,988
Management Meetings/Professional Development		0		0	61,250	61,250
Non-ICASS Administrative Costs		0		0	244,702	244,702
Staff Program Travel				0	345,000	345,000
USG Staff Salaries and Benefits - Internationally Recruited	928,875			928,875	1,206,295	2,135,170
USG Staff Salaries and Benefits - Locally Recruited	928,875			928,875	563,125	1,492,000
Total	1,857,750	0	0	1,857,750	4,637,133	6,494,883

U.S. Department of Health and Human Services/Substance Abuse and Mental Health Services Administration

Agency Cost	GAP	GHP-State	GHP-USAID	Funding	Applied	Total All
-------------	-----	-----------	-----------	---------	---------	-----------



of Doing Business				Source Total	Pipeline	Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		25,000		25,000	0	25,000
Computers/IT Services		5,000		5,000	0	5,000
ICASS		85,000		85,000	0	85,000
Institutional Contractors				0	0	0
Management Meetings/Professional Development		2,000		2,000	0	2,000
Non-ICASS Administrative Costs		18,000		18,000	0	18,000
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		165,230		165,230	0	165,230
USG Staff Salaries and Benefits - Internationally Recruited		223,000		223,000	0	223,000
USG Staff Salaries and Benefits - Locally Recruited		91,500		91,500	0	91,500
Total	0	614,730	0	614,730	0	614,730



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		0		0	10,000	10,000
ICASS		150,000		150,000	0	150,000
Management Meetings/Professional Development		0		0	52,000	52,000
Non-ICASS Administrative Costs		0		0	144,518	144,518
Staff Program Travel		5,197		5,197	28,800	33,997
USG Renovation		0		0	30,000	30,000
USG Staff Salaries and Benefits - Locally Recruited		85,318		85,318	34,682	120,000
Total	0	240,515	0	240,515	300,000	540,515